"Illumina (ILMN) is definitely off the table," says Roche (RHHBY.PK) Chairman Franz Humer, his company walking away from a bid for the 2nd time in a year. "They were not willing to abandon the totally unrealistic price they were asking for ... There are several alternatives to get hold of gene-sequencing technology."
"Illumina (ILMN) is definitely off the table," says Roche (RHHBY.PK) Chairman Franz Humer, his...
From other sites
Video at CNBC.com (Jun 28, 2016)
Video at CNBC.com (Apr 19, 2016)
Video at CNBC.com (Oct 6, 2015)
at CNBC.com (Jan 9, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs